DOCSLIB.ORG

Sexual Side Effects of Psychiatric Medications in Women: a Clinical Review

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Sexual Side Effects of Psychiatric Medications in Women: a Clinical Review Jefferson Journal of Psychiatry Volume 12 Issue 1 Article 11 January 1994 Sexual Side Effects of Psychiatric Medications in Women: A Clinical Review Laura L. Post, MD, FAACS University of California at San Francisco Follow this and additional works at: https://jdc.jefferson.edu/jeffjpsychiatry Part of the Psychiatry Commons Let us know how access to this document benefits ouy Recommended Citation Post, MD, FAACS, Laura L. (1994) "Sexual Side Effects of Psychiatric Medications in Women: A Clinical Review," Jefferson Journal of Psychiatry: Vol. 12 : Iss. 1 , Article 11. DOI: https://doi.org/10.29046/JJP.012.1.008 Available at: https://jdc.jefferson.edu/jeffjpsychiatry/vol12/iss1/11 This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital Commons is a service of Thomas Jefferson University's Center for Teaching and Learning (CTL). The Commons is a showcase for Jefferson books and journals, peer-reviewed scholarly publications, unique historical collections from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and interested readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been accepted for inclusion in Jefferson Journal of Psychiatry by an authorized administrator of the Jefferson Digital Commons. For more information, please contact: [email protected]. Sexual Side Effects ofPsychiatric Medications in Women: A Clinical Review Laura L. Post, MD , FAACS Abstract Sexual side dficts ofpsychiatric medications have been estimated to occur in 60% ofmale clients (1) and 30%offemale clients (2). Despite a bodyofliterature relating individual medications to specific sexual side dficts, fe to studies have satisfactorily addressed the psychotropic-induced sexual dysfunctions in women. The spectrum ofknoton sexual sidedficts resultingfrompsychophar­ macologic interventions will be reviewed. GuidelinesJOr appropriately addressing the possibility qf sexual side effects within a therapeutic relationship.for maximizing reporting ofsexual side dficts, andforpossible treatment approaches to sexual sidedficts will be described. INTRODUCTION The pa st twenty years have shown a dramat ic surge in the a pproaches to and tools of bio logical psychi atry. Concomitant with th ese advances has eme rge d aware­ ness of psychotropic-induced se xual side effects. These side effects may con tribute to physiological morbidity, to e mba rrassme nt and sh ame, to non complian ce, to stress­ induced sym ptom exace rba tion, and, argu ably, to mistrust of psychi at ric pr actit io­ ners.Representa tives ofseveral classes of psychiatric medi cations- including bcn zo­ diaz epines, beta-blockers, lit hium, monoamine oxidase inhibitors, neu rol ep tics, and tri- and tetra-cyclic a ntide pressa nts- ha ve been reported to ca use so me form of se xua l impairment. Kn own sexua l side effects associated with psych otropi cs include anorgasmia (3) , un satisfyin g or painful or gasm (4), alte re d libid o or sex ua l willing ness, erectile failure, priapi sm (5), menstrual irregul arities, delayed or ret rograd e ejacula tion (6) , a nd alte red sexual se nsation and se nsitivity (7,8).Yet , th e se xual side effects of psych o-pharmaceuticals are still a mo ng th e most subtle, least discu ssed , and poorly understood conseq ue nce s of modern medi cal treatments. The psychiatric lit erature contains numerous case reports but few well-designed research studies addressing sexual side effec ts (9). This knowl ed ge ga p may reflect widespread erotophobic attitudes, skewed funding a nd educational prio rit ies around th e importan ce of human se xuality, or inad equa te training of pr escribers in eliciting sexua l side effec ts from clients. Laura L. Post , M.D. , recently complete d her res ide ncy in Psychi at ry at th e Langley Porter Psych iatric Institute of th e University ofCalifornia in Sa n Francisco. 75 76 JEffERSON JO URNAL OF PSYCHIATRY In add ition, very few of th e existing studies include fe male subjects (10,11,1 2); those that do oft en fail to separat e outcomes by ge nde r, rendering problematic th e drawing of conclus ions relevant to wom en clients. The lack ofa tt en tion to incid en ces a nd expe riences of psych otropi c-gen erat ed sexual side effec ts in wom en may occur for several reason s. First , th e ease of measurement of ma le se xual arousal (e rec tio n) an d orgasm (ejacula tion) , a nd th e rela tive simplicity of male e ndocrine fun ction s, may have contributed to a research bias towa rd male subjects, Second, th e sexual emo tions, respon ses, a nd beh aviors of wome n a re fre que ntly constrained by cult ur ally­ based and se xist crite ria; th e sa me cult ura l se xism may reduce t he mo tivation for th e compre he ns ive examina tion of th e pot ential ac tio ns of psychiatric medication s on female sex ua lity. (T his hypothesis is somewha t supporte d by the dearth of publish ed information on ge neral female sexua l function). Third, th e na rrow definiti on s of fe male sexual dysfunction may result in incon sist ent re po rt ing or inap propriat e dat a analysis. For example, qu eryin g lesbia n clients abo ut int ercourse may be irrelevant; not qu erying wom en specificall y about fantasy, a bout lubrication, abo ut ejacula tion, or abo ut th e size, shape, sensitivity, and se nsation of br east s, vagina, and clitoris may lead to om ission of vit al informa tion. Finally, th e subjectivity inh erent in t he determi na tion and describing of sex ua l impai r ment may lead to variations between studies, introducing difficulty in com pil­ ing dat a: there is a difference bet wee n libido and orgasm. Nevertheless, th e available reports do suggest so me ge neral patterns of sexual sid e effec ts, in wom en , from psych ot ropics. SUMMARY OF PSYCH OTROPI C-IND UCED SEXUAL DYSFUNCTIO NS IN WO~IE N In female patients, several psychopharmacologic agents have been implicat ed as causative of sexual side effects. Alprazolam (13), amoxapine (14) , clomipramine (15,16, 17), diazepa m ( 18), fluphenazine ( 19), flurazepam (20) , imipramine (21,22), MAGIs (2 1,23,24,25,26), thiorid azin e (27) , a nd t rifluoroperazine (27) hav e all been spec ifica lly rep ort ed to inhibit orgasm . Fenflura mine has been reported to enha nce orgasm (28). Howeve r, th e story is not so st raightforward. Desipra mine has been rep orted to ca use anorgasmia (29) and not to cause anorgasmia (22) . Fluox etine has been reported to in hib it orgasm (30,3 1,26) and to e nha nce orgasm (32) . Simila rly, trazod one has been re ported to increase (33) and decrease (34) libido. PERSPECTI VES ON PHARMACOSEXO LOGY T he rela tionship between psychiatric medi cations and resultant se xua l dysfunc­ tion is complex. Animal models suggest that sexual fun ction is dep endent upon ce ntrally-acting dopa mi ne agonists and is inhibited by th e se ro tone rgic syste m (35). In hu man males, decr eases in libido have been attributed to anti-dopam inergic and se ro to nergic effec ts (36), as well as to limbic fluctua tion s and to decreased levels of endogeno us opioids and test ost erone (37). Hu ma n male erec tion, medi at ed SEX UAL SIDE EFFE CTS OF PSYCHIATRIC MEDI CATIONS IN WOM EN 77 principally by autonomic neurons, may be diminish ed: a) by interferen ce with central dopaminergic output (38) ; b) by interferen ce with bet a-adren ergic ac tivity or by enha nceme nt of a lphaj-ad rc ne rg ic transmission (39); c) by int erferen ce with th e choline rg ic spinal reflex es necessary for erection; or d) by interruption of th e neuronal-hematological fillin g of the co rpora. Human male ejacula tion, m ediat ed by alpha I-ad re ne rg ic receptors, may be a n tagonized by alphaI-ad re ne rgic blo ckade. Human mal e orgasm [which is no t neces sarily identical with ej ac ula tion], thought to be ce nt ra l in origin, may be elim ina te d by serotonergic age nts (40). Cl early, th e se ro to ne rg ic agonism, th e dopaminergic a nd cholinergic blo ckade, and alphaI-ad re ne rg ic effec ts res ult ing from some psychiat ric medications might aIte r sexual function in ma le clients (41) . Though anatomic analogies m ay be made between male a nd fe male libido, between male erection and female lubrication/labi al swelling, between m ale ejacula­ tion and female ejaculation, and between male and female orgasm , th e neu rophysiol­ ogy of female sexuality-animal or human-is less com plete ly understood th an the male counterpart. Conclusions about effe cts, on women , of a n ti-do pamine rgic , anti-a lpha r-adre nc rgic, anticholinergic, and serotonergic effec ts remain th eoret ical a nd sp eculative. CLINICAL DISCUSSION AND GUIDELINES Psychotropic-induced sexual sid e effec ts may be ameli orat ed with bioch em icall y­ informed interventions.
Load more

Recommended publications
  • Australian Product Information Parlodel® (Bromocriptine Mesilate)
    AUSTRALIAN PRODUCT INFORMATION PARLODEL® (BROMOCRIPTINE MESILATE) TABLET AND HARD CAPSULE 1 NAME OF THE MEDICINE Bromocriptine mesilate 2 QUALITATIVE AND QUANTITATIVE COMPOSITION • Parlodel tablets and capsules contain bromocriptine mesilate • Oral tablets: ➢ 2.5 mg bromocriptine (present as 2.9 mg mesilate). • Oral capsules: ➢ 10 mg bromocriptine (present as 11.5 mg mesilate). ➢ 5 mg bromocriptine (present at 5.735 mg mesilate). • List of excipients with known effect: lactose and sugars. • For the full list of excipients, see Section 6.1 List of excipients. 3 PHARMACEUTICAL FORM Oral tablets: • White, coded XC with breakline on one side, SANDOZ on the other side. Oral capsules: • 5 mg: opaque white and opaque blue, marked PS • 10 mg: opaque white 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS • Prevention of onset of lactation in the puerperium for clearly defined medical reasons. Therapy should be continued for 14 days to prevent rebound lactation. Parlodel should not be used to suppress established lactation. • Treatment of hyperprolactinaemia where surgery and/or radiotherapy are not indicated or have already been used with incomplete resolution. Precautions should be taken to ensure that the hyperprolactinaemia is not due to severe primary hypothyroidism. Where the cause of hyperprolactinaemia is a prolactin-secreting microadenoma or macroadenoma, Parlodel is indicated for conservative treatment; prior to surgery in order to reduce tumour size and to facilitate removal; after surgery if prolactin level is still elevated. • Adjunctive therapy in the management of acromegaly when: (1) The patient refuses surgery and/or radiotherapy (2) Surgery and/or radiotherapy has been unsuccessful or full effects are not expected for some months (3) A manifestation of the acromegaly needs to be brought under control pending surgery and/or radiotherapy.
    [Show full text]
  • Aphrodisiac Herbal Therapy for Erectile Dysfunction
    Original Article Aphrodisiac Herbal therapy for Erectile Dysfunction Bharti Goel1, Neelesh Kumar Maurya2* 1Research Scholar Department of Foods and Nutrition, Government Home Science College, Panjab University, Chandigarh, India. 2 Research Scholar, Department of Foods and Nutrition, Institute of Home Science, Bundelkhand University, Jhansi, Uttar Pradesh, India. Abstract Erectile dysfunction (ED) or male impotence is described as an inability to maintain penile erection primarily endothelial and neuronal dysfunction which is partly characterized by decreased production of nitric oxide (NO). Male impotence can be caused by androgen deficiency in aging men, atherosclerosis, diabetes mellitus, spinal cord injury, high level of cholesterol, hypertension, prostate surgery, prostate and heart disease, penis anatomical deformity, social and psychological conditions as unhappy marital relationship, depression, and stress. Aphrodisiac is a drink or food that arouse sexuality. It can be categorized into three groups according to their action mode as follows: increase sexual pleasure substances, increase libido substances (arousal, sexual desire), and increase sexual potency (erection effectiveness). Various extracts of medicinal plants and orally active drugs such as vardenafil, sildenafil, and tadalafil are used to increase arterial blood flow for treating (ED) in southwest Asia. Hence, this paper review focuses on medicinal plants used as aphrodisiacs for scientific validation and management of erectile dysfunction (ED). Keywords: Aphrodisiacs, herbal plants, erectile dysfunction, penile erection INTRODUCTION care providers, testosterone replacement therapy for aging men has been practiced for many years but if the patient has Erectile dysfunction (ED) is a neurovascular condition that no clinical signs of androgen deficiency then testosterone involves endothelium of the corpora cavernosal arterial blood replacement therapy will have no clinical effect [13, 14].
    [Show full text]
  • Schizophrenia Care Guide
    August 2015 CCHCS/DHCS Care Guide: Schizophrenia SUMMARY DECISION SUPPORT PATIENT EDUCATION/SELF MANAGEMENT GOALS ALERTS Minimize frequency and severity of psychotic episodes Suicidal ideation or gestures Encourage medication adherence Abnormal movements Manage medication side effects Delusions Monitor as clinically appropriate Neuroleptic Malignant Syndrome Danger to self or others DIAGNOSTIC CRITERIA/EVALUATION (PER DSM V) 1. Rule out delirium or other medical illnesses mimicking schizophrenia (see page 5), medications or drugs of abuse causing psychosis (see page 6), other mental illness causes of psychosis, e.g., Bipolar Mania or Depression, Major Depression, PTSD, borderline personality disorder (see page 4). Ideas in patients (even odd ideas) that we disagree with can be learned and are therefore not necessarily signs of schizophrenia. Schizophrenia is a world-wide phenomenon that can occur in cultures with widely differing ideas. 2. Diagnosis is made based on the following: (Criteria A and B must be met) A. Two of the following symptoms/signs must be present over much of at least one month (unless treated), with a significant impact on social or occupational functioning, over at least a 6-month period of time: Delusions, Hallucinations, Disorganized Speech, Negative symptoms (social withdrawal, poverty of thought, etc.), severely disorganized or catatonic behavior. B. At least one of the symptoms/signs should be Delusions, Hallucinations, or Disorganized Speech. TREATMENT OPTIONS MEDICATIONS Informed consent for psychotropic
    [Show full text]
  • UNJ February 03
    Man’s Search for Ultimate Sex: Viagra® Abuse Jeffrey A. Albaugh Susan Kellogg-Spadt n an age when men aspire for “extreme” perfor- mance in all aspects of their lives, sexual per- safe, but encouraged the young man to seek medical formance is no exception. As a result, the drug advice prior to further use. Curiosity about Viagra sildenafil citrate (Viagra®) is being routinely abounds with men wondering about its ability to Iused and abused by men of all ages (who have not improve the quality and rigidity of erections, been diagnosed with erectile dysfunction) to facili- decrease the refractory period after ejaculation, and tate the ultimate sexual experience. Men might use increase libido. Danner (2001) reports that Viagra is this drug to counteract or coincide with other recre- one of the “party drugs” of our times and there are ational drugs, to improve the quality and longevity reports that it is prevalent in British nightclubs and of an already adequate erection, or to shorten the restaurants under the name “poke” (Canadian normal physiologic refractory period between erec- Medical Association, 1998). Widespread Viagra use tions. Although there is no indication or document- is also reported as a trend among gay men in the ed evidence for improved erectile function in party scene (Contemporary Sexuality, 2001; Men’s healthy young men, the use of sildenafil citrate Fitness, 2002). among this population is thought to improve erec- tile longevity and rigidity by these men. Mixing Drugs Man’s search for improved sexual function In recreational use, Viagra is being mixed with would be better served by his learning about the other street drugs such as ecstasy (methylene- arousal response cycle and the type and amount of dioxymethamphetamine), uppers (amphetamines), loveplay that might lead his partner to the greatest crystal methadone, and poppers (amyl nitrate) into level of satisfaction.
    [Show full text]
  • Bromocriptine-A Changing Scene
    LONDON, SATURDAY 20 DECEMBER 1975 Br Med J: first published as 10.1136/bmj.4.5998.667 on 20 December 1975. Downloaded from MEDICAL JOURNAL Bromocriptine -a changing scene Ergot, known to man since ancient times, is a product of the Levodopa has been used to lower prolactin levels, but its fungus Claviceps purpurea that grows on rye and grain. A action does not last long enough; bromocriptine has a much symposium' at the Royal College of Physicians last May longer action and is therefore more effective. reviewed the pharmacology and clinical uses of the older as Since bromocriptine has been shown not to be teratogenic it well as the more recently introduced ergot compounds. All the has been used recently in restoring fertility. Its place has still ergot alkaloids are derivatives of lysergic acid: the best known finally to be defined, but it appears to be effective not only in are the oxytocic ergometrine and the mixed ao-adrenergic patients with hyperprolactinaemia but also in some with agonist and antagonist ergometrine compounds. Nevertheless, normal prolactin levels, as described by M 0 Thorner et al,14 the first group of ergot compounds isolated by Barger, Carr, at p 694 of this issue. There is, however, some danger in and Dale in 1906, and called ergotoxine,2 is a mixture of ergot restoring fertility in women with small pituitary tumours, alkaloids: ergocornine, ergocristine, and ergokryptine. since such lesions may rapidly enlarge, with visual impairment, The inhibition oflactation by ergot was described by Dodart3 during pregnancy. Arguably the tumour should be irradiated in 1676.
    [Show full text]
  • Sexual Arousal and Performance Are Modulated by Adrenergic-Neuropeptide- Steroid Interactions
    * 1995 Elsevier Science B. V. All rights reserved. The Pharmacology of Sexual Function and Dysfunction J. Bancroft, editor 55 Sexual Arousal and Performance are Modulated by Adrenergic-Neuropeptide- Steroid Interactions John T. Clark Department of Physiology, Meharry Medical College, 1005 D.B. Todd Boulevard, Nashville, Tennessee, 37208, U.S.A. Introduction Sexual function is regulated by a complex interaction between the nervous system, hormones and sexually relevant tissues. In addition to psychogenic causes, organic factors such as aging, hypertension, diabetes, renal failure, malnutrition, and obesity, as well as responses to medications used to treat these disorders, may all contribute to sexual dysfunction. Although the precise identification of the neurochemical messengers (and the appropriate neuroanatomical loci) underlying the expression of male sexual behavior remains to be elucidated, progress has been made. We feel that, with careful attention paid to the aspects of sexuality and the problems associated with continuous (or long-term) pharmacological/hormonal treatment, some degree of relief may be available for those exhibiting sexual dysfunction In our research in male rats, we have frequently observed a repression of sexual function. However, some treatments do facilitate aspects of sexual behavior. We have repeatedly observed two "prosexual" effects in male rats: a facilitation of the ejaculatory response; and a facilitation of sexual arousal. Other prosexual effects have been reported, typically an enhancement of erection. Assessment of Sexual Function Animal modeling of human sexual function is viable, and its usage is aimed at elucidating the biological factors affecting male sexual behavior [1-5]. Although it seems reasonable to test drugs for sexual effects in animals first, many clinically useful agents (including antihypertensives) have not been systematically studied.
    [Show full text]
  • Drugs for Parkinson's Disease
    Australian Prescriber Vol. 24 No. 4 2001 Drugs for Parkinson’s disease V.S.C. Fung, M.A. Hely, Department of Neurology, G. De Moore, Department of Psychiatry and J.G.L. Morris, Department of Neurology, Westmead Hospital, Westmead, New South Wales SYNOPSIS Levodopa commonly causes nausea, especially when treatment Levodopa is the most effective drug available for treating begins. This nausea results from the conversion of levodopa to the motor symptoms of idiopathic Parkinson’s disease. It dopamine which stimulates the dopamine receptors in the area is usually combined with a peripheral dopa decarboxylase postrema (‘vomiting centre’) in the brainstem, a structure which inhibitor. Early treatment with dopamine agonists can lies outside the blood-brain barrier. The nausea is minimised by reduce the risk of developing dyskinesia. Dopamine agonists introducing levodopa slowly, starting with a low dose, taking it and catechol-O-methyltransferase inhibitors can with food and giving it in combination with a peripheral dopa significantly reduce motor fluctuations. Amantadine decarboxylase inhibitor such as carbidopa or benserazide. A reduces the severity of dyskinesia in some patients. No minimum daily dose of 75 mg is necessary to adequately inhibit treatment has been proven to delay disease progression. the production of dopamine outside the blood-brain barrier. Metoclopramide and prochlorperazine should be avoided as Index words: amantadine, dopamine, entacapone, they are dopamine antagonists and make parkinsonism worse. levodopa, selegiline. If an antiemetic is required, domperidone 10–20 mg three times (Aust Prescr 2001;24:92–5) daily is the drug of choice as it is a dopamine antagonist which does not cross the blood-brain barrier.
    [Show full text]
  • “Rauwolscine/ Alfa Yohimbine”
    “Rauwolscine/ Alfa Yohimbine” Rauwolscine / Alfa Yohimbine – Natural and Safe Alternative for FAT BURNING Rauwolscine or Alfa–Yohimbine is an indole alkaloid with stimulant, aphrodisiac and local anaesthetic effects found naturally in plants of the genus Rauwolfia and Pausinystalia, along with several other active alkaloids including Yohimbine. Rauwolscine is a stereoisomer of Yohimbine, that is it is chemically identical, but differs in its 3 dimensional orientation. There are a total of 3 stereoisomers of Yohimbine, the other two are corynanthine and 3-epi-alpha-yohimbine. How it works – science behind this natural supplement Fat-Burning Potential Rauwolscine, or {3H}Rauwolscine, is a potent and selective antagonist of alpha-2 adrenergic receptors. This is the same mechanism by which yohimbine acts by blocking the pre- and post-synaptic alpha-2 adrenoceptors, this prevents the release of Norepinephrine from cells. Norepinepherine stimulates both the alpha and beta receptors in a cell. Stimulation of the beta adrenoceptors causes the breakdown of fat, whilst stimulating the alpha-2 adrenoceptors prevents this breakdown of fats.Alfa Yohimbine (Rauwolscine) blocks the alpha feedback mechanism, thus increasing norepinephrine. Additionally in blocking the alpha-2 receptor it blocks the storage of new fat. Serotonergic Effects Its works in a similar fashion like yohimbine, rauwolscine is an agonist of 5-HT1a/b receptors and induces serotonin-like effects.Whereas yohimbine has more affinity for the receptor, rauwolscine has a lower IC50 value (meaning it can saturate more receptors at the same dose) and can be seen as slightly more potent in serotonergic activity. Rauwolscine, an antagonist radioligand for the cloned human 5- hydroxytryptamine2b (5-HT2B) receptor.
    [Show full text]
  • Bromocriptine Monograph, Compendium of Pharmaceuticals and Specialties
    Bromocriptine DRUG NAME: Bromocriptine SYNONYM(S): COMMON TRADE NAME(S): APO-BROMOCRIPTINE®, PMS-BROMOCRIPTINE® CLASSIFICATION: hormonal agent Special pediatric considerations are noted when applicable, otherwise adult provisions apply. MECHANISM OF ACTION: Bromocriptine is a dopaminergic ergot derivative.1 Bromocriptine may decrease hormone production and the size of prolactin-dependent pituitary adenomas2,3 by inhibiting the release and synthesis of prolactin from the anterior pituitary gland.1 PHARMACOKINETICS: Interpatient variability variable GI absorption and first pass metabolism contributes to variability in plasma concentrations and dose response Oral Absorption rapidly absorbed, 28-95%4 Distribution only 7% of the dose reaches systemic circulation unchanged due to first pass metabolism cross blood brain barrier?5 yes volume of distribution no information found plasma protein binding 96% Metabolism primarily hepatic, high hepatic extraction rate and first pass metabolism active metabolite(s) no information found inactive metabolite(s)2 lysergic acid and a peptide fragment Excretion primarily hepatic urine2 3-6% feces2,4,6 95% via bile terminal half life 2-8 h; metabolites: 50-70 h clearance no information found Adapted from standard reference1 unless specified otherwise. USES: Primary uses: Other uses: *Pituitary tumours *Health Canada approved indication SPECIAL PRECAUTIONS: Contraindications1,7: • history of hypersensitivity reaction to ergot derivatives • uncontrolled hypertension Caution: • may cause hypotension1; see paragraph
    [Show full text]
  • Sildenafil-Associated Hepatoxicity: a Review of the Literature
    European Review for Medical and Pharmacological Sciences 2017; 21 (1 Suppl): 17-22 Sildenafil-associated hepatoxicity: a review of the literature S. GRAZIANO1, A. MONTANA2, S. ZAAMI3, M.C. ROTOLO1, A. MINUTILLO1, F.P. BUSARDÒ3, E. MARINELLI3 1Drug Abuse and Doping Unit, Department of Therapeutic Research and Medicines Evaluation, Istituto Superiore di Sanità, Rome, Italy 2Laboratory of Forensic Toxicology, Department “G.F. Ingrassia”, University of Catania, Catania, Italy 3Unit of Forensic Toxicology (UoFT), Department of Anatomical, Histological, Forensic and Orthopedic Sciences, Sapienza University of Rome, Rome, Italy Abstract. – Sildenafil citrate (Viagra®) is a Introduction vasoactive agent available worldwide since 1998 for the treatment of male erectile dysfunction. It Sildenafil citrate (Viagra®) is a vasoactive is a selective phosphodiesterase type 5-enzyme agent, which became available worldwide in 1998 inhibitor able to potentiate the downstream ef- for the treatment of male erectile dysfunction. fects of nitric oxide on smooth muscle relaxa- tion and vasodilation through its effects on the The drug acts by inhibiting the phosphodiester- cyclic guanosine monophosphate (c-GMP) path- ase type 5 (PDE5) enzymes that specifically way in the erectile tissue of the penis. When degrade the cyclic guanosine monophosphate sildenafil is orally administered, it is rapidly ab- (cGMP), responsible for the nitric oxide induced sorbed with a maximum plasma concentration smooth muscle relaxation and vasodilatation1. achieved within 1 h and has a terminal half-life PDE5 is found in particularly high concentration of between 3 to 6 h. The drug is extensively and in the corpus cavernosum, the erectile tissue rapidly metabolized by the liver, primarily by of the penis; it is also found in the retina and the CYP3A4 enzyme.
    [Show full text]
  • Name of Medicine
    HALDOL® haloperidol decanoate NEW ZEALAND DATA SHEET 1. PRODUCT NAME HALDOL haloperidol decanoate 50 mg/mL Injection HALDOL CONCENTRATE haloperidol decanoate 100 mg/mL Injection 2. QUANTITATIVE AND QUALITATIVE COMPOSITION HALDOL 50 mg/ml Haloperidol decanoate 70.52 mg, equivalent to 50 mg haloperidol base, per millilitre. HALDOL CONCENTRATE 100 mg/ml Haloperidol decanoate 141.04 mg, equivalent to 100 mg haloperidol base, per millilitre. For a full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Injection (depot) HALDOL Injection (long acting) is a slightly amber, slightly viscous solution, free from visible foreign matter, filled in 1 mL amber glass ampoules. 4. CLINICAL PARTICULARS 4.1 Therapeutic indications HALDOL is indicated for the maintenance therapy of psychoses in adults, particularly for patients requiring prolonged parenteral neuroleptic therapy. 4.2 Dose and method of administration Administration HALDOL should be administered by deep intramuscular injection into the gluteal region. It is recommended to alternate between the two gluteal muscles for subsequent injections. A 2 inch-long, 21 gauge needle is recommended. The maximum volume per injection site should not exceed 3 mL. The recommended interval between doses is 4 weeks. DO NOT ADMINISTER INTRAVENOUSLY. Patients must be previously stabilised on oral haloperidol before converting to HALDOL. Treatment initiation and dose titration must be carried out under close clinical supervision. The starting dose of HALDOL should be based on the patient's clinical history, severity of symptoms, physical condition and response to the current oral haloperidol dose. Patients must always be maintained on the lowest effective dose. CCDS(180302) Page 1 of 16 HALDOL(180712)ADS Dosage - Adults Table 1.
    [Show full text]
  • Package Leaflet: Information for the User Parlodel 2.5 Mg Tablets Bromocriptine Mesilate
    Package leaflet: Information for the user Parlodel 2.5 mg Tablets Bromocriptine mesilate Read all of this leaflet carefully before you start taking this medicine because it contains important information for you. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor or pharmacist. - This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. - If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. What is in this leaflet: 1. What Parlodel tablets are and what it is used for 2. What you need to know before you take Parlodel tablets 3. How to take Parlodel tablets 4. Possible side effects 5. How to store Parlodel tablets 6. Contents of the pack and other information 1. WHAT PARLODEL TABLETS ARE AND WHAT IT IS USED FOR Parlodel tablets contain the active ingredient bromocriptine, which belongs to a group of medicines called dopamine agonists and prolactin inhibitors. Parlodel tablets are used for: Treatment of Parkinson’s disease. Treatment of prolactinomas (a non-cancerous tumour of the pituitary gland in the brain). Co-treatment of acromegaly with surgery or radiotherapy. Acromegaly is abnormal growth caused by high levels of growth hormone. Treatment of hyperprolactinaemia (abnormally high levels of prolactin causing unexplained milk secretion and irregular periods in women and lack of sex drive in men). Treatment of menstrual cycle disorders and female infertility caused by hyperprolactinaemia (see above).
    [Show full text]